Interní Med. 2008; 10(2): 54-57

Biological drugs in colorectal cancer treatment

Jindřich Fínek
Chirurgická klinika FN Plzeň

Colorectal cancer ranks the second most common cause of cancer death in Europe. It accounted for 13% (413 000 incident cases) of all newly diagnosed cancers and for about 20% (335 000 deaths) cancer deaths in 2006. Treatment strategies involving combination of chemotherapy and biological treatment are prolonging the survival of cancer patients with advanced colorectal cancer.

Keywords: colorectal cancer, chemotherapy, bevacizumab, cetuximab

Published: May 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fínek J. Biological drugs in colorectal cancer treatment. Interní Med. 2008;10(2):54-57.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adam R, Aloia T, Lévi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastatses previously refractory to conventional systemic therapy. J Clin Oncol 2007; 2: 4593-4602. Go to original source... Go to PubMed...
    2. Dias S, et al. Autocrine stimulation of VEGFR - 2 activates human leukemic cell growth and migration J. Clin. Invest. 2000; 106: 511-521. Go to original source... Go to PubMed...
    3. Fan F, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005; 24: 2647-2653. Go to original source... Go to PubMed...
    4. Ferrara N, et al. Discovery and development of bevacizumab. An anti-VEGF antibody for treating cancer. Nature Rev. Drug Discov. 2004; 3: 391-400. Go to original source... Go to PubMed...
    5. Folkman J. Tumor angiogenesis: therapeutic implicantions. N. Engl. J. Med 1971; 285: 1182-1186. Go to original source... Go to PubMed...
    6. Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med 2004; 350: 2335-2342. Go to original source... Go to PubMed...
    7. Jain RK. Normalization of tumor vasculature, an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62. Go to original source... Go to PubMed...
    8. Journal of Clinical Oncology. 2007 ASCO Annual Meeting Proceedings Part I, Vol. 25, No 18S (June 2005 Supplement), 2007: 4000 Crystal. Saltz LB etv al. Randomised Phase II Trial of Cetuximab, Bevacizumab and Irinotecan compared with cetuximab and Bevacizumab alone in Irinotecan Regractory Colorectal Cancer: The Bond 2 Study. J Clin Oncol. 2007; 25: 4557-4561. Go to original source... Go to PubMed...
    9. Saltz LB, et al. Interim report of randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus versus cetuximab/ bevacizumab (CB) in irinotecan-refracory colorectal cancer. Proc. ASCO Gastrointestinal Cancers Symp. A 169b (2005). Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.